BRISBANE, Calif., Feb. 14 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapeutics, announced that Hoyoung Huh, M.D., Ph.D., has been appointed President and Chief Executive Officer and will commence his new role on March 3, 2008.
Dr. Huh previously served as Chief Operating Officer and Head of the Pegylation Business Unit at Nektar Therapeutics, a drug development company in the therapeutic areas of oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led significant, revenue-generating partnerships with major pharmaceutical companies including Amgen Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG and Roche Holding Ltd. Dr. Huh managed more than 500 employees across global sites in key functions including research, clinical development, manufacturing, marketing and business development. He was also instrumental in establishing multiple new product partnerships and led the acquisition and divestiture of several entities.
Prior to Nektar, Dr. Huh was a partner with McKinsey & Company, serving biotechnology, biopharmaceutical and healthcare clients in the United States, Europe and Asia. He has been an industry thought leader and frequent speaker on topics including licensing, mergers and acquisitions and innovative product development and commercialization strategies. Dr. Huh serves on the board of directors of BayBio, a biotechnology industry association, and Nektar Therapeutics.
"Hoyoung is ideally suited to lead BiPar through this period of
expansion and change, with a robust Phase 2 program underway with BSI-201,
a potential best-in-class cancer therapy," said G. Kirk Raab, chairman of
BiPar, who had served as acting CEO prior to Dr. Huh's appointment. "His
business development experience is exceptional, and there is no doubt that
Hoyoung will maximize the value of BiPar's programs through rigorous
clinical development and w
|SOURCE BiPar Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved